Connect with us

Business

how InvestingPro’s fair value models predicted Fluor’s 68% surge

Published

on

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

10 Foods That Doctors and Registered Dietitians Recommend for People Living With Pancreatic Cancer Now

Published

on

Egg

Maintaining proper nutrition during pancreatic cancer treatment presents unique challenges that most other cancer diagnoses do not, according to oncology dietitians and medical centers that specialize in the disease. Because the pancreas plays a central role in digesting food and regulating blood sugar, cancer affecting the organ can directly interfere with a patient’s ability to absorb nutrients, maintain weight and manage energy levels throughout treatment.

Medical experts emphasize that there is no single standardized diet that works for every pancreatic cancer patient. “There’s no one-size-fits-all diet,” Emma Veilleux, a registered dietitian nutritionist at the Simms/Mann-UCLA Center for Integrative Oncology, said, noting that foods that help one patient may worsen symptoms in another. Even so, several categories of food have emerged as consistent recommendations across major cancer centers and patient advocacy organizations. Here are 10 foods commonly recommended for people managing pancreatic cancer.

1. Lean poultry and fish. Protein-rich foods that are relatively easy to digest, such as chicken, turkey and fish, are widely recommended because they support the body’s ability to repair damaged tissue and maintain immune function during treatment, according to guidance from Johns Hopkins Medicine. Lean proteins are generally easier on the digestive system than fattier cuts of meat.

2. Eggs. Eggs offer a highly digestible source of protein and are frequently recommended as an easy addition to meals throughout the day, particularly for patients who struggle with larger portions and benefit from smaller, protein-dense foods that can be prepared quickly.

Advertisement

3. Low-fat Greek yogurt. Yogurt provides protein along with probiotics that may support digestive health, though dietitians note that dairy tolerance varies significantly among patients. Some people develop temporary lactose intolerance during treatment and may need to limit or avoid dairy products depending on how their body responds.

4. Beans and legumes. Plant-based protein sources such as beans, lentils and chickpeas provide protein, fiber and a range of micronutrients. Well-cooked legumes, including options like lentil soup, are frequently recommended because they tend to be gentler on digestion than some other high-fiber foods.

5. Nuts and nut butters. Almond, cashew and peanut butters offer concentrated calories, healthy fats and protein in small serving sizes, making them useful for patients who need to increase calorie intake but struggle to eat large meals. Nut butters spread on whole-grain crackers or toast are a commonly suggested snack option.

6. Fatty fish, including salmon. Fish such as salmon provide healthy unsaturated fats that supply energy and support cell function without the digestive difficulty that greasy or fried foods can cause. Baked or grilled preparations are typically recommended over fried versions.

Advertisement

7. Well-cooked vegetables. Colorful vegetables such as zucchini, carrots, spinach and sweet potatoes provide essential vitamins, minerals and fiber. Nutrition guides for pancreatic cancer patients generally recommend cooking or blending vegetables rather than eating them raw, since raw vegetables can be harder to digest for patients with compromised pancreatic function.

8. Whole grains, including oatmeal and quinoa. Complex carbohydrates such as oatmeal and quinoa provide steady energy and fiber, and are often recommended as a base for meals that also include protein and healthy fats, helping patients manage blood sugar levels more effectively than simple carbohydrates or refined sugars.

9. Soft fruits, including berries and bananas. Fruits that are easy to digest, such as mashed bananas and soft berries, provide vitamins, antioxidants and natural sweetness without the blood sugar spikes associated with added sugars. The World Cancer Research Fund International recommends at least five servings of non-starchy vegetables and fruits daily as part of broader cancer nutrition guidance, though individual tolerance should guide specific choices for pancreatic cancer patients.

10. Healthy fats, including olive oil and avocado. Unsaturated fats support cell growth, provide concentrated energy and help protect organ function, according to Johns Hopkins Medicine guidance. These fats are generally easier to tolerate than the greasy, fried or heavily processed fats found in many convenience foods, which oncology dietitians frequently recommend limiting or avoiding.

Advertisement

Beyond specific food choices, dietitians who specialize in pancreatic cancer care emphasize several broader strategies. Many patients benefit from eating smaller, more frequent meals throughout the day rather than three large meals, particularly if appetite changes or early fullness make larger portions difficult to manage. Patients experiencing exocrine pancreatic insufficiency, a condition in which the pancreas no longer produces enough digestive enzymes, often require prescription pancreatic enzyme supplements taken with meals to properly digest fats and absorb nutrients, according to the Pancreatic Cancer Action Network.

Unintentional weight loss is a common and serious concern for pancreatic cancer patients, sometimes driven by the cancer itself rather than simply reduced appetite. Tumors can release compounds called cytokines into the bloodstream that suppress appetite and accelerate calorie burning, a condition known as cancer cachexia. Patients experiencing weight loss of more than one to two pounds per week are generally advised to consult their care team promptly, as early intervention with nutritional supplements, calorie-dense foods or changes to enzyme dosing can help address the problem before it becomes more severe.

Certain foods are commonly advised against for pancreatic cancer patients, including fried and greasy foods, processed and red meats, foods high in added sugar, and raw or undercooked items linked to foodborne illness risk, such as raw sushi, unpasteurized dairy and deli meats, given that cancer treatment can weaken immune function and increase vulnerability to infection.

Because nutritional needs vary so significantly from patient to patient, and can change throughout the course of treatment, medical organizations including the Pancreatic Cancer Action Network and Johns Hopkins Medicine consistently recommend that patients work directly with an oncology-trained registered dietitian who can develop an individualized nutrition plan based on symptoms, treatment side effects, blood sugar management needs and overall tolerance for specific foods, rather than relying solely on general dietary guidelines.

Advertisement
Continue Reading

Business

Hammerson declares 9.67 pence interim dividend for 2026

Published

on


Hammerson declares 9.67 pence interim dividend for 2026

Continue Reading

Business

Motilal Oswal raises mid and smallcap allocation to 50%, stays neutral on Indian equities

Published

on

Motilal Oswal raises mid and smallcap allocation to 50%, stays neutral on Indian equities
Mumbai: Motilal Oswal Private Wealth is overweight on Indian mid- and small-caps, although it maintains a neutral stance on Indian stocks. The money manager for deep pockets is increasing allocations by 10 percentage points to 50%, while suggesting a 40% allocation to hybrids and large caps. The rest – 10% – should include global equities.

“We have increased our overweight to mid- and small-caps given their stronger representation in high-growth, new-economy sectors and the improvement in valuations,” said Sandipan Roy, chief investment officer, Motilal Oswal Private Wealth.

Motilal Oswal Bats for Mid & Small CapsAgencies

Wealth manager recommends 50% allocation to the sector and 40% to hybrids & large caps

For hybrid strategies, he recommends lump sum deployment at current levels, while pure equity-oriented strategies should be staggered given prevailing uncertainties. Roy said meaningful corrections could be entry points for aggressive exposures.

Read more: Can Manipal Health IPO deliver long-term growth for high risk investors?

Advertisement

While large-cap capital goods exposure is concentrated in a limited set of established engineering companies, the midcap and smallcap universe represents a wider cross-section of India’s capex cycle.

Even in the case of healthcare the exposure in mid and small cap indices extends well beyond pharmaceuticals-capturing hospitals, diagnostics, biotechnology, CDMO, medical devices and healthcare technology, which are high growth areas.
The wealth manager points out that FII flows are rotating away from benchmark-heavy sectors such as Financials, IT, FMCG and autos towards industrial and manufacturing themes like capital goods and metals, which have higher mid and small cap representation, thus reflecting improving FII preference for manufacturing led small and midcap opportunities.

Continue Reading

Business

HWL Ebsworth, UWA sued over data breach

Published

on

HWL Ebsworth, UWA sued over data breach

Yes. Corporate subscriptions are available for teams and organisations, with discounted rates as user numbers increase. Pricing starts from $1,625 + GST per user.
Get in touch
to discuss the right option for your organisation.

Business News subscriptions are used by executives, investors, consultants and professionals who need to stay informed and make better decisions about the WA market. When you subscribe you’ll get

  • Unlimited access to WA’s most trusted business journalism
  • Data & Insights — detailed profiles of WA companies, people, projects and deals
  • MyBN — a personalised feed based on the companies, people and sectors you follow
  • Special publications and industry reports
  • Daily and weekly email newsletters

Data & Insights is a research tool built specifically for the WA market. It draws on more than 30 years of Business News reporting, updated regularly to reflect what’s happening now. Use it to:

  • Look up detailed profiles of WA companies, including financials, directors and ownership
  • Find decision-makers and track their career movements
  • Research live and completed projects across WA industries
  • Monitor deals, appointments and market activity
  • Access industry rankings and league tables

Data & Insights is updated daily by our dedicated research team, which uses the latest announcements, ASX filings and editorial coverage to keep our person, company, list and project records up to date.

Business News welcome all opportunities to make our dataset accurate, complete and current, so if you have an update request, please email the team at
general@businessnews.com.au, and we’d be happy to assist.

Advertisement

MyBN
is part of every subscription. It’s your personalised view of Business News. You can follow the companies, people, sectors and projects that matter to you, and get a news feed and alerts tailored to your interests. You can save articles to read later and retain only what you need.

Only subscribers have full access to all content on the Business News website.

Advertisement

If staying informed about the WA economy is part of your job, and/or you’re looking for networking opportunities in WA, Business News is built for you.

Business News subscribers are:

  • Executives and directors tracking competitors, clients and market movements
  • Investors and advisers researching companies, deals and industry trends
  • Consultants and professionals staying across sectors relevant to their clients
  • Business owners looking for leads, context and market intelligence

Most Business News publications cover national or global markets. Business News is focused entirely on Western Australia, which means the journalism, the data and the intelligence are all built around WA companies, people and projects — not adapted from a national feed. Data & Insights, included with every subscription, combines more than 30 years of WA-specific editorial research with live business data. There’s no comparable product for the WA market.

Advertisement

The Morning Digest Email provides a comprehensive wrap of the major headlines, relevant to WA business, and includes with a snapshot of the overnight news covering oil, gold and ASX-listed companies.

The Afternoon Wrap Email focuses on the news covered by our team of journalists during the course of the working day, including exclusive stories and analysis, all of which relates to WA business and the local economy.

The BN Weekender Email contains a wrap of the Business News from the week that was, highlighting the top stories in each area of WA business.
Sign up for free.

Advertisement

We’re happy to help.
Get in touch
and our team will come back to you.

Advertisement
Continue Reading

Business

Engineering firm behind Center Parcs and Lidl schemes appoints administrators

Published

on

Business Live

Paramount Structures is an award-winning consultancy with six offices across the UK

Paramount Structures was involved with the design of Center Parcs Longford Forest in Ireland

Paramount Structures was involved with the design of Center Parcs Longford Forest in Ireland(Image: Irish Mirror)

A Gloucestershire-headquartered engineering firm that had worked on projects for Center Parcs, Lidl and Premier Inn has appointed administrators.

Paramount Structures Limited was established in 2008 and offers structural engineering and design services from its six UK offices in Moreton-in-Marsh, Edinburgh, Corby, Bournemouth, Chichester and Lisburn in Northern Ireland.

It was behind a number of multimillion-pound schemes including a new music facility for Wells Cathedral School, a Center Parcs forest resort in Ireland and a student accommodation block for Exeter University.

Domestic projects included the structural design of a sailing club for Christian Youth Enterprises and a Yoo Lakes private estate scheme in the Cotswolds.

Advertisement

“Our team provides everything from comprehensive design drawings to skilled and environmentally friendly engineering,” a statement on the company’s website states. “We truly believe that if it can be drawn, it can be engineered to work.”

Paramount’s directors are Gordy Nelson (chief executive), Emma Nelson (managing director) and Mark Kirk (technical director).

According to a notice on the Gazette – the UK public records site – the business appointed John Hedger of business recovery and insolvency firm Seneca on July 20.

It is not known why Paramount, which is part of the Structural Timber Association and the Concrete Society, appointed administrators or whether the business is at risk of closure.

Advertisement

Documents on Companies House show the business filed a satisfaction of charge in full – meaning it settled an outstanding debt – on July 22.

In the latest set of accounts available, for the year ended December 2024, the company had assets of £769,230 and net liabilities – or debt – of £81,947. Capital and reserves at the time stood at £47,227 – down from £162,699 in 2023. The average number of people employed by the company at the time was 12.

Just two months ago, Paramount was hiring for an ‘experienced structural engineer’ based in Scotland, according to LinkedIn, but the business has not posted on Facebook or Instagram since October last year.

Business Live has contacted the administrators and Paramount for comment.

Advertisement

The Gazette notice advises people to contact Michelle Shaw of Seneca on 01629 761700 or at Michelle.Shaw@seneca-ip.co.uk for more information on the administration.

Continue Reading

Business

Boss achieves revised FY26 guidance

Published

on

Boss achieves revised FY26 guidance

Boss Energy managing director Matthew Dusci says despite a challenging year, he is confident about the company’s pathway forward.

Continue Reading

Business

Xiaomi Shares Soar Nearly 9% as Investors Get Set for Thursday Debut of Its New N90 and N70 SUV Cars

Published

on

toyota logo

Shares of Xiaomi jumped 8.95% on Wednesday to close at 31.88 Hong Kong dollars, adding 2.62 Hong Kong dollars, as investors positioned ahead of the Chinese technology company’s launch event for two new sport utility vehicle models scheduled for Thursday.

The rally builds on gains from earlier in the week, with Xiaomi shares having already climbed as much as 7.7% on Monday to reach their highest level since June 3, according to trading data. The company confirmed that its Pengcheng launch event will take place Thursday, featuring the debut of two new SUV models, the N90 and N70, marking Xiaomi’s latest push to expand its rapidly growing electric vehicle business beyond its origins as a smartphone and consumer electronics maker.

Xiaomi entered the automotive market relatively recently, launching its first vehicle, the SU7 sedan, roughly two years ago after building its business for more than a decade primarily around smartphones, household appliances and other smart consumer devices. Since then, the company has moved aggressively to expand its vehicle lineup, with the upcoming N90 and N70 SUVs representing its latest step toward becoming a more diversified automaker alongside established Chinese electric vehicle players.

Xiaomi’s push into the SUV segment follows months of steady delivery growth for the company’s existing vehicle lineup. The company reported its third consecutive month of surpassing 30,000 monthly vehicle deliveries in June, with cumulative shipments from January through June totaling more than 180,000 units, according to data cited by Citi. That figure represented approximately 33% of Xiaomi’s full-year 2026 delivery target of 550,000 vehicles, leaving the company on a pace that analysts have described as broadly consistent with meeting its annual goal, particularly with additional models like the N90 and N70 set to expand its addressable market.

Advertisement

Citi analysts have suggested that Xiaomi’s stock could see further gains in the weeks ahead tied specifically to the rollout of its new SUV models, including a previously announced luxury SUV called the YU9, which the bank said could support a rebound in shares following its expected launch. Analysts have also pointed to broader dynamics within China’s memory chip sector as a potential additional tailwind for Xiaomi shares, given the company’s investment ties to the domestic chip industry.

That connection was highlighted earlier this week when CXMT, a Chinese memory chip manufacturer backed in part by Xiaomi, made its trading debut and saw its shares soar more than 500% on the first day of trading, instantly establishing the company as the fourth-largest global producer of dynamic random access memory chips by market position. The blockbuster debut for CXMT appeared to provide an additional boost to sentiment around Xiaomi more broadly, given the strategic relationship between the two companies.

Xiaomi’s broader business results have shown substantial growth over the past year even as the stock’s performance has been volatile. The company’s full-year 2025 results showed earnings per share of 1.62 Chinese yuan, up from 0.95 yuan in the prior year, while revenue climbed 25% to 457.3 billion yuan and net income rose 76% to 41.6 billion yuan, pushing the company’s profit margin up to 9.1% from 6.5% a year earlier.

Even so, some analysts have grown more cautious on the company’s near-term earnings trajectory in recent weeks. Consensus forecasts for Xiaomi’s fiscal 2026 earnings per share have been revised downward, with the current outlook calling for 1.13 yuan per share, down from an earlier estimate of 1.56 yuan, while the 2026 revenue forecast has been trimmed to approximately 501.1 billion yuan from a prior estimate of 544.6 billion yuan. Net income for the coming year is now forecast to shrink 29%, a notable divergence from the roughly 32% growth rate currently projected for the broader technology industry in Hong Kong. Analyst consensus price targets have also moved lower in recent weeks, dropping to 44.67 Hong Kong dollars from a previous target of 47.84 Hong Kong dollars.

Advertisement

Despite those more cautious revisions, Xiaomi’s stock has still delivered strong returns to shareholders over a longer time horizon, with total returns of approximately 128% over the past three years, according to recent analyst compilations, even as the shares have experienced significant volatility along the way, including a period earlier this year when the stock was down more than 34% on a year-to-date basis before staging a substantial recovery.

Wednesday’s gains for Xiaomi came alongside broader strength across Hong Kong’s technology sector, with the Hang Seng Index opening higher and the Hang Seng Tech Index climbing more than 1% at the start of the session. Other major Chinese technology names also advanced, including Tencent, Alibaba, Meituan and JD.com, reflecting a generally positive tone across Hong Kong-listed technology stocks even as investors continued to monitor broader volatility in global semiconductor markets tied to concerns about artificial intelligence infrastructure spending.

Investors are expected to closely watch Thursday’s Pengcheng event for further details on pricing, specifications and expected delivery timelines for the N90 and N70 models, which will offer the clearest signal yet of how aggressively Xiaomi intends to compete against established rivals in China’s crowded and rapidly evolving electric vehicle market.

Advertisement
Continue Reading

Business

Airbus A350 completes 24-hour test flight for Qantas’ Project Sunrise

Published

on

Airbus A350 completes 24-hour test flight for Qantas’ Project Sunrise

Airbus completed a test flight lasting more than 24 hours, a key step toward Qantas’ planned nonstop service linking Australia and Europe.

The aircraft – a specially adapted A350-1000ULR – flew 14,338 miles from Melbourne, Australia, to Toulouse, France, in 24 hours and 24 minutes, according to Flightradar24 data.

Advertisement

The flight was a major test for Qantas’ Project Sunrise, launched in 2017 to create the world’s longest nonstop commercial routes.

FAA SCALES BACK AMERICAN AIRLINES NATIONWIDE GROUND STOP AFTER SYSTEMWIDE IT OUTAGE

An Airbus A350-100ULR after landing at Melbourne Airport

An Airbus A350-1000ULR lands at Melbourne Airport on July 24, 2026, after completing a 19-hour, 12-minute flight from Toulouse, France. The aircraft is being tested for Qantas’ Project Sunrise. (James D. Morgan/Getty Images)

Airbus has been testing the aircraft as part of a two-month campaign that began in June.

The journey surpassed a 2005 Boeing flight, when a 777-200LR Worldliner traveled 13,422 miles from Hong Kong to London in 22 hours and 42 minutes.

Advertisement

More than 3.6 million people followed the test flight on Flightradar24, making it the platform’s second-most-tracked flight ever, according to the flight-tracking service.

RYANAIR PASSENGER RECOUNTS BEING PARTLY SUCKED OUT AIRPLANE WINDOW: ‘I AM LUCKY’

Qantas' Ultra-long-range Project Sunrise Airbus A350 Jetliner

An Airbus A350-1000ULR sits on the tarmac at Melbourne Airport after a 19-hour, 12-minute flight from Toulouse, France, on July 24, 2026.  (James D. Morgan/Getty Images)

The aircraft features an additional fuel tank capable of carrying roughly 20,000 additional liters (5,283 pounds) of fuel and can seat 238 passengers.

Qantas has ordered 12 of the jets. The first is expected to be delivered in April 2027, with daily nonstop flights between Sydney and London planned for October 2027.

Advertisement

“Each cabin has been luxuriously crafted with innovative designs and materials to deliver ultimate comfort on what will be the longest commercial flight in the world,” Qantas said on its website.

NEW BOEING AIRCRAFT DEVELOPMENT HAMPERED BY BACKLOG OF EXISTING ORDERS, SAYS CEO

A Qantas A350-1000ULR arrives at Melbourne's Tullamarine Airport

A Qantas A350-1000ULR arrives at Melbourne’s Tullamarine Airport on July 24, 2026, following a 19-hour, 13-minute delivery flight from Airbus’ factory in Toulouse, France. The aircraft features an additional fuel tank. (William WEST / AFP via Getty Images)

Stocks In This Article:

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The route is expected to take about 19 to 21 hours, depending on winds and the flight path.

Advertisement

Reuters contributed to this report.

Continue Reading

Business

Can Manipal Health IPO deliver long-term growth for high risk investors?

Published

on

Can Manipal Health IPO deliver long-term growth for high risk investors?
ET Intelligence Group: Manipal Health Enterprises, a healthcare service provider, plans to raise ₹8,000 crore through a fresh issue for repayment of debt, acquisition of stake in the subsidiary and general corporate purposes. It will also raise ₹1,275 crore through an offer for sale.

The promoter group’s stake will fall to 72.1% after the IPO from 81.4%. Around 46% of the revenue comes from Karnataka, signalling geographic concentration. Its occupancy rate declined to 64.5% in FY26 from 67.1% a year ago.

Read more: Motilal Oswal raises mid and smallcap allocation to 50%, stays neutral on Indian equities

The company’s revenue growth was strong in the past two years, but it faced margin pressure. The issue also appears to be aggressively priced. Given these factors, investors may wait to see clarity post listing.

Manipal Health Seen in Good Health, but Comes at a PremiumAgencies

Lower occupancy, margin pressure a concern

Business
Incorporated in 2010, Manipal Health Enterprises, a part of the Manipal Group, offers a wide range of healthcare services including tertiary and quaternary care, organ transplants, oncology, cardiology, neurology, orthopaedics, and preventive healthcare.

Advertisement


As of March 31, 2026, the company operated 49 hospitals with 13,037 licensed beds and 21 clinics. The company has occupancy of 64.5%, compared with 67-76% for its peers. Its average length of stay is also lower at 2.8 days compared with peers which is between 3.2 and 4.2 days.
Over 64% of its revenue is derived from cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics, and renal sciences (CONGO-R) specialties.According to Crisil report, Manipal Health Enterprises is the largest pan-India multispecialty hospital network by bed capacity and also the second largest hospital chain by number of hospitals as of March 31, 2026 after Apollo Hospitals.

Financials
Revenue from operations grew 29.4% annually to ₹10,335.8 crore and net profit rose 31.1% to ₹916.5 crore between FY24 and FY26. Operating profit before interest, tax, depreciation and amortisation (Ebitda) increased 24.8% to ₹2,644.1 crore during the period. On a year-on-year basis, revenue grew 25.4%, Ebitda rose 22.1% while net profit declined 15.3% in FY26. Ebitda margin dropped to 25.6% in FY26 from 27.5% in FY24. Cash flow from operations grew 32.4% to ₹2,078.4 crore in FY26 over FY25. Average revenue per occupied bed grew 5.7% annually to ₹68,937.61 over FY24-26.

Valuation
Considering the post-IPO equity and net profit for FY26, the company demands a price-earnings (P/E) multiple of 85, quite higher than its peers, which is between 62-68 for Apollo Hospitals Enterprise, Max Healthcare Institute and Fortis Healthcare.

Continue Reading

Business

Positive Breakout: These 8 stocks cross above their 200 DMAs

Published

on

The Economic Times

As of July 29, 2026, 18 Nifty 500 stocks closed above their 200-day moving average (DMA). Among them, we highlighted the top eight that gained more than 4%, based on StockEdge.com’s technical scan data. The 200-day daily moving average (DMA) is used by traders as a key indicator for determining the overall trend in a particular stock. As long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend. Take a look:”

Continue Reading

Trending

Copyright © 2025